COMMUNIQUÉS West-GlobeNewswire

GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621
08/01/2026
New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA JOLLA, CA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. ( [...]
RESTEM Provides Corporate Update and Announces Strategic Priorities for 2026
08/01/2026
MIAMI, Jan. 08, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today provided a corporate [...]
CytomX Therapeutics Announces Business Update and Company Milestones for 2026
08/01/2026
- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”) Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 [...]
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia
08/01/2026
Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine Findings also [...]
Nautilus Biotechnology Launches Early Access Program for Novel Single-Molecule Proteomics Platform, Starting with Tau Proteoforms Assay
08/01/2026
Early Access Program participants receive exclusive use of Nautilus’ Iterative Mapping method, initially through a validated tau proteoforms assay, with the potential to accelerate Alzheimer’s and neurodegenerative [...]
Navigator Medicines Accelerates Anti OX-40L and TNFα Bispecific Antibody Clinical Development Pipeline into Phase 2a and First-in-Human Trials
08/01/2026
FDA Clears IND Allowing Phase 2a Trial of NAV-240 in Hidradenitis Suppurativa to Begin Dosing in Q1 2026 HREC Approval Received for Next-Generation Bispecific NAV-242 to Initiate First-in-Human Phase 1 Program with Ph1a [...]
R1 Launches Phare Audit, the AI-Native Solution to Capture Full Reimbursement, Reduce Revenue Leakage and Improve Quality
08/01/2026
Phare Audit Uses Proprietary Agentic AI to Maximize Earned Reimbursement, Enhancing R1’s Industry-Leading DRG-V with Full Auditability CHICAGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in [...]
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes
08/01/2026
PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune [...]
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
08/01/2026
Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with [...]
Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer
08/01/2026
KUALA LUMPUR, Malaysia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (NASDAQ: ALPS) (the “Company” or “Alps Group”), a fully integrated biotechnology research and healthcare platform specializing in predictive, [...]
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
08/01/2026
Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE [...]
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights
08/01/2026
Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the placebo group Topline healthy volunteer data from Phase 1 study of next- [...]
Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa
08/01/2026
GAITHERSBURG, Md. and PARIS and ADDIS ABABA, Ethiopia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced a collaboration agreement with PANTHER to provide additional financial support [...]
Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
08/01/2026
MELBOURNE, Australia and INDIANAPOLIS, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will [...]
Aclarion Provides 2025 Update and 2026 Corporate Outlook
08/01/2026
Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025 Annual Nociscan scan volumes increased 69% year-over-year in 2025 Debt-free balance sheet with $12.0 million in cash as of December 31, 2025, [...]
Human Appeal’s new subsidiary, The Waqf Fund, launched into $700 billion global market
08/01/2026
To promote charitable funds for long-term humanitarian projects MANCHESTER, United Kingdom, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Leading UK humanitarian aid charity, Human Appeal, today announces the launch of a new [...]
Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)
08/01/2026
ORION CORPORATION PRESS RELEASE 8 JANUARY 2026 at 12.00 EET Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE) [...]
Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort
08/01/2026
-- Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of AGMB-447 in healthy participants -- -- Pharmacokinetic profile in healthy [...]
EnteroBiotix announces positive Phase 2 TrIuMPH results supporting EBX-102-02 as a potential first-in-class, oral, full-spectrum microbiome therapy for irritable bowel syndrome
08/01/2026
Clinically meaningful improvements in global IBS symptom severity observed as early as Week 1 and sustained through Week 7, with EBX-102-02 outperforming placebo throughout the study (final assessment at Week 7) Durable [...]

Pages